novidades científicas Novo

16:13 European Cardiovascular Disease Statistics 2017
10:47 CETP inhibitor meets primary endpoint in CV outcome study
9:54 Arrhythmias and devices
14:31 Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
14:18 Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Hospital Performance Based on 30-Day Risk Standardized Mortality and Long-Term Survival after Hearth Failure Hospitalization an Analysis of the GWTG-HF Registry

14 Março 2018

Todos os estudos aqui apresentados podem ser consultados na íntegra no site do American College of Cardiology

http://www.acc.org/education-and-meetings/image-and-slide-gallery

Tags:
ACC 2018

Lower Risk of Cardiovascular Events and Death Associated with Initiation of SGLT-2 Inhibitors Versus Other Glucose Lowering Drugs - Real World Data Across Three Major World Regions With More Than 400.000 Patients: The CVD-REAL 2 Study

14 Março 2018
0

Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) - Long Term Outcomes

14 Março 2018
0

-->